Pfizer is a general drug manufacturer company located in New York, United States, which is part of the Healthcare sector, and is traded under the ticker PFE on the NYSE exchange.
Pfizer stock last closed at $26.58, down 2.49% from the previous day, and has increased 1.26% in one year. It has underperformed other stocks in the Drug Manufacturers - General industry by 0.17 percentage points. Pfizer stock is currently +27.09% from its 52-week low of $20.92, and -4.87% from its 52-week high of $27.94.
As of Mar 3, 2026, there are 5.69B shares of PFE outstanding. The market cap of PFE is $151.14B. In the last 24 hours, 33.9M PFE shares were traded.
You will need an online brokerage account to access the NYSE market and buy PFE stock.
We believe that eToro is the best brokerage. eToro gives you:
Get $10 towards your share purchase by signing up for an account with eToro today. This offer is only for US users.
Open eToro AccountNow that you've picked your brokerage, you'll need to fill out some personal info so you are able to invest in PFE today.
Now that you have filled out your info on one of the most highly reviewed stock trading apps, you can securely and quickly fund your account:
Watch the walkthrough below for more details transferring funds into your new investment account.
After you have figured out the best place to buy Pfizer stock, it's very important to research their stock prior to investing, so you truly understand the risk as well as the upside.
WallStreetZen was created to help everyday investors do more accurate fundamental analysis.
You can view all of the due diligence checks on PFE's stock page.
You can use a variety of different financial metrics, analyses, models, and charts to gauge PFE's intrinsic value.
Using relative valuations metrics:
You can do more valuation research on PFE's stock here.
Out of 10 Equities analysts who give ratings on PFE, the consensus analyst rating on PFE is a Hold
Please keep in mind that analyst forecasts are not recommendations, nor are they investment advice.
Terence Flynn, a top 6% analyst from Morgan Stanley maintains PFE with a hold rating and lowers their PFE price target from $28.00 to $27.00, on Dec 17, 2025.
Jason Gerberry, a top 16% analyst from Bank of America maintains PFE with a hold rating and lowers their PFE price target from $29.00 to $28.00, on Dec 15, 2025.
Geoff Meacham, a top 12% analyst from Citigroup reinstates PFE with a hold rating and announces their PFE price target of $26.00, on Dec 2, 2025.
Vamil Divan, a top 3% analyst from Guggenheim maintains PFE with a strong buy rating and raises their PFE price target from $33.00 to $35.00, on Nov 24, 2025.
Tim Anderson, a top 24% analyst from Bank of America maintains PFE with a hold rating and raises their PFE price target from $28.00 to $30.00, on Oct 3, 2025.
Bank of America's Tim Anderson raised their price target on Pfizer (NYSE: PFE) by 7.1% from $28 to $30 on 2025/10/03. The analyst maintained their Hold rating on the stock.
In a sector review note on names in their large-cap biopharma portfolio, Anderson said that although the timing of President Trump's drug pricing announcement with Pfizer was a surprise, the substance was "pretty benign overall, triggering "a partial re-rating of many, but not all, of the stocks in the group.
The analyst added that they adjusted "select" price targets in the group to account for those re-ratings, "as well as other fundamental changes."
You can dig deeper into what analysts are saying on the Pfizer stock forecast page.
Last year, PFE earnings were $7.77B. Over the past 5 year, PFE's earnings have grown by -3.65% per year. This was slower than the Drug Manufacturers - General industry average of 19.61%.
Last year, PFE revenue was $62.58B. During the last 5 year, PFE's revenue has gone up by 8.48% per year. This was slower than the Drug Manufacturers - General industry average of 10.06%.
You can research PFE's earnings and revenue performance here.
In the past 12 months, executives and large shareholders at PFE have bought more shares than they have sold.
Jennifer B. Damico, SVP Controller of PFE, was the latest PFE insider to sell. They sold $18,110.75 worth of PFE shares on Feb 27, 2026.
Get more info about who owns PFE stock here.
Pfizer pays a dividend of 4.85%, compared to the Drug Manufacturers - General industry's average dividend yield of 2.6%. If you owned $1,000 of PFE stock, you would have been paid $48.53 last year.
Pfizer dividend payments have consistently grown over the past decade and have remained stable.
Find more info about Pfizer dividend yield and history here.
One of the major reasons eToro is our top-rated brokerage is because of its social trading community.
Click below to see what other community members have to say.
You have two primary types of orders:
Hit the Open Trade button and your broker will place your order.
If you need more info about buying stocks on eToro, click the helpful video below:
Now that you own some PFE stock, you'll want to stay up-to-date on your investment.
Create a watchlist to see the latest developments about your PFE stock.
To summarize, here are the 6 steps to buy stock in Pfizer:
If you are looking for a place to buy stocks, eToro is our favorite venue.
Get Started with eToro TodayIf you would like to keep an eye on your investment in Pfizer, get started below.